SCHEMBL9263449

SCHEMBL9263449

COc1ccc(C(=O)CCC(=O)O)cc1Cl

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.57
CYP1A2 P05177 1/20 0.57
HPGD P15428 1/20 0.57
CYP2C19 P33261 1/20 0.57
HSD17B10 Q99714 1/20 0.57
POLB P06746 1/20 0.55
MAPT P10636 1/20 0.55
CTNNB1 P35222 2/20 0.55
WNT3A P56704 2/20 0.55
STING1 Q86WV6 3/20 0.52
PDE4B Q07343 1/20 0.50
TAS1R3 Q7RTX0 1/20 0.49
TAS1R1 Q7RTX1 1/20 0.49
USP5 P45974 1/20 0.49
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.48
NPC1 O15118 1/20 0.48
HTT P42858 1/20 0.48
RAB9A P51151 1/20 0.48
KCNH2 Q12809 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3950960 0.86 TAS1R3 (0.57) ALDH1A1POLBMAPTCTNNB1WNT3A
SCHEMBL29923058 0.85 CTNNB1 (0.73) ALDH1A1CYP1A2HPGDCYP2C19HSD17B10
SCHEMBL1527427 0.85 CTNNB1 (0.73) ALDH1A1CYP1A2HPGDCYP2C19HSD17B10
SCHEMBL4257689 0.85 KMT2A (0.55) ALDH1A1CYP1A2HPGDCYP2C19HSD17B10
SCHEMBL5188941 0.83 ALDH1A1 (0.59) ALDH1A1CYP1A2HPGDCYP2C19HSD17B10
SCHEMBL5495178 0.83 CTNNB1 (0.60) ALDH1A1CYP1A2HPGDCYP2C19HSD17B10
SCHEMBL30449245 0.82 TAS1R3 (0.45) ALDH1A1CYP1A2HPGDCYP2C19POLB
SCHEMBL29032173 0.82 TAS1R3 (0.45) ALDH1A1CYP1A2HPGDCYP2C19POLB
SCHEMBL6136939 0.82 TAS1R3 (0.53) ALDH1A1CYP1A2CYP2C19POLBMAPT
SCHEMBL12780432 0.82 MEN1 (0.59) ALDH1A1CYP1A2HPGDCYP2C19POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240182452-A1 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER BAYER AKTIENGESELLSCHAFT (DE) 2024-06-06 US disclosed
US-11897867-B2 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives as PDE3A and PDE3B inhibitors for treating cancer BAYER AKTIENGESELLSCHAFT (DE) 2024-02-13 US disclosed
CN-116249691-A Bicyclic derivative regulator, preparation method and application thereof 上海翰森生物医药科技有限公司 2023-06-09 CN disclosed
EP-3661917-B1 6-((3-TRIFLUOROMETHYL)PHENYL)-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER BAYER AG (DE) 2022-05-11 EP disclosed
US-20210077431-A1 N-(2-(SUBSTITUTED-NAPHTH-1-YL)ETHYL) SUBSTITUTED AMIDE COMPOUND, PREPARATION AND USES THEREOF BEIJING GREATWAY PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2021-03-18 US disclosed
US-20200247783-A1 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER BAYER AKTIENGESELLSCHAFT (DE) 2020-08-06 US disclosed
EP-3661917-A1 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER Bayer Aktiengesellschaft (DE) 2020-06-10 EP disclosed
WO-2019025554-A1 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER BAYER AKTIENGESELLSCHAFT (DE) 2019-02-07 WO disclosed
US-5428168-A Substituted butyrolactol ether derivative BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1995-06-27 US disclosed
EP-0527817-A1 GAMMA-BUTYROLACTOL ETHER DERIVATIVES BRITISH BIO-TECHNOLOGY LIMITED (GB) 1993-02-24 EP disclosed
WO-1991017157-A1 GAMMA-BUTYROLACTOL ETHER DERIVATIVES BRITISH BIO-TECHNOLOGY LIMITED (GB) 1991-11-14 WO disclosed
US-4052395-A AGRICULTURAL FUNGICIDAL COMPOSITIONS CONTAINING 6-(SUBSTITUTED PHENYL)-PYRIDAZINONES AND SAID PYRIDAZINONES SANKYO COMPANY LIMITED (JA) 1977-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240182452-A1 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER PDE3A, PDE3B, PDE5A ALDH1A1 118/4885CYP1A2 365/4885HPGD 71/4885
US-20200247783-A1 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER PDE3B, PDE3A, PDE5A ALDH1A1 53/4885CYP1A2 262/4885HPGD 272/4885
US-11897867-B2 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives as PDE3A and PDE3B inhibitors for treating cancer PDE3B, PDE3A, PDE5A ALDH1A1 53/4885CYP1A2 262/4885HPGD 272/4885
US-20210077431-A1 N-(2-(SUBSTITUTED-NAPHTH-1-YL)ETHYL) SUBSTITUTED AMIDE COMPOUND, PREPARATION AND USES THEREOF MTNR1A, HTR2C, MTNR1B ALDH1A1 2141/4885CYP1A2 291/4885HPGD 1492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.